Monoclonal antibodies against claudin-18 for treatment of cancer
AssigneesGanymed Pharmaceuticals AG, Johannes Gutenberg-Universitat Mainz
InventorsUgur Sahin, Ozlem Tureci, Dirk Usener, Stefan Fritz, Cristoph Uherek, Gunda Brandenburg, Harald-Gerhard Geppert, Anja Kristina Schroder, Philippe Thiel
Life of this patent
Estimating the term…
Abstract
The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.
Claims5
An antibody produced by a clone deposited under the accession no. DSM ACC2737, DSM ACC2739, DSM ACC2742, DSM ACC2745, DSM ACC2748, DSM ACC2808, DSM ACC2809, or DSM ACC2810.
A hybridoma deposited under the accession no. DSM ACC2737, DSM ACC2739, DSM ACC2742, DSM ACC2745, DSM ACC2748, DSM ACC2808, DSM ACC2809, or DSM ACC2810.
Dependencies are inferred from the claim text.